HC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX)

HC Wainwright reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report released on Friday,Benzinga reports. They currently have a $15.00 price objective on the stock.

A number of other equities research analysts have also issued reports on the company. Wedbush reissued an “outperform” rating and issued a $10.00 target price on shares of TScan Therapeutics in a research report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a report on Tuesday, November 12th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $12.00.

TScan Therapeutics Stock Performance

Shares of TCRX opened at $4.41 on Friday. The firm has a market cap of $233.60 million, a P/E ratio of -4.16 and a beta of 0.79. TScan Therapeutics has a twelve month low of $3.73 and a twelve month high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.77 and a current ratio of 9.56. The firm’s 50 day moving average price is $5.31 and its two-hundred day moving average price is $6.46.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $2.86 million. On average, analysts forecast that TScan Therapeutics will post -1.14 EPS for the current fiscal year.

Insider Activity

In other TScan Therapeutics news, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the sale, the insider now owns 4,716 shares in the company, valued at $27,258.48. This trade represents a 97.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the purchase, the director now directly owns 35,000 shares in the company, valued at $199,150. The trade was a 16.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 15,000 shares of company stock valued at $82,550. 2.76% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TCRX. Tocqueville Asset Management L.P. bought a new stake in TScan Therapeutics in the 1st quarter valued at $1,685,000. Vanguard Group Inc. lifted its stake in shares of TScan Therapeutics by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after buying an additional 20,000 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of TScan Therapeutics during the 2nd quarter worth about $682,000. Rhumbline Advisers acquired a new position in TScan Therapeutics in the 2nd quarter valued at about $274,000. Finally, American Century Companies Inc. grew its stake in TScan Therapeutics by 48.9% in the 2nd quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock valued at $278,000 after buying an additional 15,596 shares during the last quarter. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.